News from delmar pharmaceuticals A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 27, 2015, 09:35 ET

DelMar Pharmaceuticals Announces Financing Update and Initial Subscriptions of $2.0 million in Registered Direct Offering

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing...

Jul 20, 2015, 07:35 ET

DelMar Pharmaceuticals Expands GBM Clinical Trial with Fifth Clinical Trial Site Added in Denver, Colorado

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and...

Jul 09, 2015, 07:35 ET
Jun 15, 2015, 08:05 ET

DelMar Pharmaceuticals Invited to Present at The World NSCLC Summit on June 23-24, 2015

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing...

Jun 10, 2015, 08:35 ET

DelMar Pharmaceuticals to Present at the BIO International Convention on June 17, 2015

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing...

Jun 01, 2015, 14:29 ET

DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and...

Jun 01, 2015, 08:35 ET

DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing...

May 29, 2015, 07:35 ET

DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing...

May 27, 2015, 07:05 ET

DelMar Pharmaceuticals Announces Upcoming Investor and Scientific Conference Presentations

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on...

May 18, 2015, 08:05 ET

DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2015 Financial Results and Provides Corporate Update

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing...

May 07, 2015, 08:05 ET

DelMar Pharmaceuticals to Present Additional Data on VAL-083 as a Potential Treatment for Temozolomide-Resistant GBM at AACR Advances in Brain Cancer Research Conference

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing...

Apr 30, 2015, 07:05 ET

DelMar Pharmaceuticals to Present Data Supporting the Development of VAL-083 in Refractory Glioblastoma Multiforme and Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), today announced that it will be presenting new data related to the...

Apr 20, 2015, 13:00 ET

DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM)

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing...

Apr 20, 2015, 08:00 ET

DelMar Pharmaceuticals Presents Updated Clinical Data on Phase I/II Study of VAL-083 in Refractory Glioblastoma Multiforme (GBM)

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing...

Apr 19, 2015, 13:00 ET

DelMar Pharmaceuticals Presents Positive Preclinical Data on VAL-083 for Treatment of Non-Small Cell Lung Cancer at the American Association of Cancer Research Annual Meeting

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven...

Apr 16, 2015, 08:05 ET

DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing...

Apr 07, 2015, 08:00 ET

DelMar Pharmaceuticals Announces Panel Participation in Cancer Advance Boston Conference on April 14, 2015

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing...

Apr 01, 2015, 08:05 ET

DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), today announced that it has appointed biopharmaceutical industry veteran,...

Mar 03, 2015, 08:00 ET

DelMar Pharmaceuticals to Present at the 27th Annual ROTH Conference on March 10, 2015

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing...

Mar 02, 2015, 11:17 ET

DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a company focused on developing and commercializing proven cancer...